Arvinas Inc (NASDAQ: ARVN) on Friday, plunged -0.98% from the previous trading day, before settling in for the closing price of $9.14. Within the past 52 weeks, ARVN’s price has moved between $5.93 and $37.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 87.40% over the past five years. The company achieved an average annual earnings per share of -38.80%. With a float of $59.90 million, this company’s outstanding shares have now reached $68.80 million.
Let’s look at the performance matrix of the company that is accounted for 430 employees. In terms of profitability, gross margin is 98.71%, operating margin of -95.03%, and the pretax margin is -75.32%.
Arvinas Inc (ARVN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arvinas Inc is 12.90%, while institutional ownership is 103.49%. The most recent insider transaction that took place on Mar 18 ’25, was worth 74,372. In this transaction Chief Medical Officer of this company sold 8,658 shares at a rate of $8.59, taking the stock ownership to the 110,023 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Officer proposed sale 8,658 for $8.59, making the entire transaction worth $74,372.
Arvinas Inc (ARVN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -38.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.94% during the next five years compared to -5.32% drop over the previous five years of trading.
Arvinas Inc (NASDAQ: ARVN) Trading Performance Indicators
Arvinas Inc (ARVN) is currently performing well based on its current performance indicators. A quick ratio of 4.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.08, a number that is poised to hit -0.96 in the next quarter and is forecasted to reach -4.16 in one year’s time.
Technical Analysis of Arvinas Inc (ARVN)
Arvinas Inc (NASDAQ: ARVN) saw its 5-day average volume 1.95 million, a negative change from its year-to-date volume of 2.02 million. As of the previous 9 days, the stock’s Stochastic %D was 93.93%. Additionally, its Average True Range was 0.66.
During the past 100 days, Arvinas Inc’s (ARVN) raw stochastic average was set at 14.81%, which indicates a significant decrease from 93.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.17% in the past 14 days, which was lower than the 134.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.24, while its 200-day Moving Average is $20.76. Nevertheless, the first resistance level for the watch stands at $9.22 in the near term. At $9.38, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.55. If the price goes on to break the first support level at $8.89, it is likely to go to the next support level at $8.72. The third support level lies at $8.56 if the price breaches the second support level.
Arvinas Inc (NASDAQ: ARVN) Key Stats
Market capitalization of the company is 622.39 million based on 68,772K outstanding shares. Right now, sales total 263,400 K and income totals -198,900 K. The company made 59,200 K in profit during its latest quarter, and -45,100 K in sales during its previous quarter.
